Source link : https://newshealth.biz/health-news/fda-oks-immunotherapy-bcg-combo-for-high-risk-bladder-cancer/
The FDA approved durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval was based on results from the phase III POTOMAC trial, which showed that adding the immune checkpoint inhibitor to BCG induction and maintenance therapy significantly improved disease-free survival (DFS) compared with BCG therapy […]
The post FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-28 19:50:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8